Business Context and Reporting Period
Company: ILLUMINA, INC.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 28, 2004
Business Overview: Illumina develops tools for large-scale genetic analysis, including SNP genotyping systems (BeadLab, BeadStation), gene expression systems, and oligonucleotides. The company is in an early commercialization stage with significant R&D expenditures and an accumulated deficit of $121.4 million as of the reporting date.
Key Financial Metrics
| Metric (in thousands) | Q1 2004 | Q1 2003 |
|---|---|---|
| Total Revenue | $10,803 | $4,276 |
| Net Loss | $(3,931) | $(8,960) |
| Loss per Share (Basic/Diluted) | $(0.12) | $(0.28) |
| Cash and Cash Equivalents | $8,740 | $4,879 |
| Total Investments (Available for Sale) | $19,049 | $20,317 |
| Long-Term Debt | $24,893 | $24,999 |
| Net Cash Used in Operating Activities | $(4,710) | $(4,977) |
| Gross Margin (Product/Service) | 72% | 42% |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 153% year-over-year, driven primarily by a 535% surge in product revenue ($8.9M vs. $1.4M). This growth is attributed to sales of consumables for BeadLab systems and the first sales of the new BeadStation benchtop system.
- Service Revenue Decline: Service revenue decreased 38% to $1.15M, largely due to the completion of a large genotyping services contract in the prior year.
- Improved Profitability Metrics: While the company remains unprofitable, the net loss narrowed significantly from $8.96M to $3.93M. Gross margins on product and service revenue improved from 42% to 72% due to higher-margin consumable sales and manufacturing efficiencies.
- Expense Trends: R&D expenses decreased 10% to $5.18M as development on key 2003 product launches concluded. Conversely, Selling, General, and Administrative (SG&A) expenses increased 25% to $5.74M due to expanded sales and marketing infrastructure, including a new operation in Singapore.
- Working Capital: Accounts receivable increased by $4.2M, reflecting higher sales volume, while cash and cash equivalents decreased by $3.7M due to operating losses and net investment activity.
Guidance, Outlook, Risks, and Contingencies
- Liquidity Outlook: Management expects current cash, investments, and grant funding to be sufficient to fund operations for at least 18 to 24 months. A shelf registration statement allowing up to $65 million in equity financing was declared effective in April 2004.
- Legal Contingencies (Applied Biosystems): A significant dispute exists with former collaborator Applied Biosystems regarding patent infringement and breach of contract. Applied Biosystems seeks damages exceeding $60 million and an injunction on sales. Illumina has not accrued for potential losses but notes a $10 million advance payment from the former collaborator could offset adverse outcomes. Arbitration is expected to conclude by September 2004.
- Litigation Judgment: A $7.7 million judgment from a 2002 employment lawsuit remains on appeal. The company is restricted from using approximately $12.5 million in marketable securities as collateral for a surety bond until the appeal is resolved. Interest expense on this judgment was $189,000 for the quarter.
- Market Risks: Revenue is subject to significant fluctuation due to reliance on a few large transactions and government grants (e.g., NIH HapMap Project). The company faces intense competition and risks related to the commercialization of unproven technologies.
Investor Verification Checklist
- Legal Exposure: Verify the status of the arbitration with Applied Biosystems and the potential impact of a $60M+ damages claim or sales injunction.
- Cash Runway: Confirm the sufficiency of the $27.9M in liquid assets (cash + investments) against the projected 18-24 month burn rate, considering the restricted $12.5M collateral.
- Revenue Sustainability: Assess whether the 153% revenue growth is sustainable given the decline in service revenue and the lumpy nature of system sales.
- Product Adoption: Monitor sales traction of the new BeadStation and Sentrix BeadChip products to ensure they offset potential declines in BeadLab system sales.
- Grant Funding: Track the disbursement of the remaining $4.9M NIH grant for the International HapMap Project, which impacts research revenue recognition.